Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.

XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.

A strategic framework has been devised with nine priority actions to enhance quality, accessibility, innovation and sustainability in trials.

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

According to the World Health Organization, autism spectrum disorder (ASD) affects approximately 10% of children globally. ASD is theorised to be caused by a combination of genetic and environmental ...

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index (BMI) in all three doses.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.